The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway

Microbial Cell Factories

Volumn 13, Issue 1, 2014, Pages

  Fleta Soriano, Eric ^a   Martinez, Javier P ^a   Hinkelmann, Bettina ^b   Gerth, Klaus ^b   Washausen, Peter ^b   Diez, Juana ^a   Frank, Ronald ^b   Sasse, Florenz ^b   Meyerhans, Andreas ^a,c  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

CRM1; HIV; Host factor; Myxobacteria; Nuclear export; Ratjadone; Rev

Indexed keywords

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIVIRAL AGENTS; CELL LINE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; KARYOPHERINS; MYXOCOCCALES; PROTEIN BINDING; PYRONES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, MESSENGER;

EID: 84892997143     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-13-17     Document Type: Article

References (62)

1. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, Gonda MA, Aldovini A, Debouk C, Gallo RC, et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986, 320:367-371. 10.1038/320367a0, 3007995.
2. Fischer U, Huber J, Boelens WC, Mattajt LW, Lührmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995, 82:475-483. 10.1016/0092-8674(95)90436-0, 7543368.
3. Henderson BR, Percipalle P. Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. J Mol Biol 1997, 274:693. 10.1006/jmbi.1997.1420, 9405152.
4. Guttler T, Gorlich D. Ran-dependent nuclear export mediators: a structural perspective. EMBO J 2011, 30:3457-3474. 10.1038/emboj.2011.287, 3181476, 21878989.
5. Dong X, Biswas A, Chook YM. Structural basis for assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 2009, 16:558-560. 10.1038/nsmb.1586, 3437629, 19339972.
6. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H, Chook YM. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009, 458:1136-1141. 10.1038/nature07975, 3437623, 19339969.
7. Cmarko D, Boe SO, Scassellati C, Szilvay AM, Davanger S, Fu XD, Haukenes G, Kalland KH, Fakan S. Rev inhibition strongly affects intracellular distribution of human immunodeficiency virus type 1 RNAs. J Virol 2002, 76:10473-10484. 10.1128/JVI.76.20.10473-10484.2002, 136536, 12239324.
8. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, De Clercq E, Pavlakis GN, Vandamme A-M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci USA 2002, 99:14440-14445. 10.1073/pnas.212285299, 137902, 12374846.
9. Hakata Y, Umemoto T, Matsushita S, Shida H. Involvement of human CRM1 (exportin 1) in the export and multimerization of the Rex protein of human T-cell leukemia virus type 1. J Virol 1998, 72:6602-6607. 109841, 9658105.
10. Lin M-H, Sivakumaran H, Apolloni A, Wei T, Jans DA, Harrich D. Nullbasic, a potent anti-HIV Tat mutant, induces CRM1-dependent disruption of HIV Rev trafficking. PLoS One 2012, 7:e51466. 10.1371/journal.pone.0051466, 3519632, 23251541.
11. Malim MH, Cullen BR. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991, 65:241-248. 10.1016/0092-8674(91)90158-U, 2015625.
12. Zapp ML, Stern S, Green MR. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 1993, 74:969-978. 10.1016/0092-8674(93)90720-B, 8402886.
13. Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function. Cell 1989, 58:205-214. 10.1016/0092-8674(89)90416-9, 2752419.
14. Stauber RH, Afonina E, Gulnik S, Erickson J, Pavlakis GN. Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells. Virology 1998, 251:38-48. 10.1006/viro.1998.9295, 9813201.
15. Szilvay AM, Brokstad KA, Boe SO, Haukenes G, Kalland KH. Oligomerization of HIV-1 Rev mutants in the cytoplasm and during nuclear import. Virology 1997, 235:73-81. 10.1006/viro.1997.8671, 9300038.
16. Kutay U, Izaurralde E, Bischoff FR, Mattaj IW, Gorlich D. Dominant-negative mutants of importin-beta block multiple pathways of import and export through the nuclear pore complex. EMBO J 1997, 16:1153-1163. 10.1093/emboj/16.6.1153, 1169714, 9135132.
17. Neville M, Rosbash M. The NES-Crm1p export pathway is not a major mRNA export route in Saccharomyces cerevisiae. EMBO J 1999, 18:3746-3756. 10.1093/emboj/18.13.3746, 1171451, 10393189.
18. Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M, Yoshida M, Horinouchi S. Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins. J Biol Chem 1997, 272:29742-29751. 10.1074/jbc.272.47.29742, 9368044.
19. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999, 96:9112-9117. 10.1073/pnas.96.16.9112, 17741, 10430904.
20. Kudo N, Wolff B, Sekimoto T, Schreiner E, Yoneda Y, Yanagida M, Horinouchi S, Yoshida M. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp Cell Res 1998, 242:540-547. 10.1006/excr.1998.4136, 9683540.
21. Gerth K, Schummer D, HÖFLE G, Irschik H, Reichenbach H. Ratjadon: a new antifungal compound from Sorangium cellulosum (myxobacteria) production, physico-chemical and biological properties. J Antibiot 1995, 48:973-976. 10.7164/antibiotics.48.973, 7592065.
22. Weissman KJ, Muller R. Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat Prod Rep 2010, 27:1276-1295. 10.1039/c001260m, 20520915.
23. Diez J, Martinez JP, Mestres J, Sasse F, Frank R, Meyerhans A. Myxobacteria: natural pharmaceutical factories. Microb Cell Fact 2012, 11:52. 10.1186/1475-2859-11-52, 3420326, 22545867.
24. Huttel S, Muller R. Methods to optimize myxobacterial fermentations using off-gas analysis. Microb Cell Fact 2012, 11:59. 10.1186/1475-2859-11-59, 3445963, 22571441.
25. Martinez JP, Hinkelmann B, Fleta-Soriano E, Steinmetz H, Jansen R, Diez J, Frank R, Sasse F, Meyerhans A. Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay. Microb Cell Fact 2013, 12:85. 10.1186/1475-2859-12-85, 3852058, 24063434.
26. Meissner T, Krause E, Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004, 576:27-30. 10.1016/j.febslet.2004.08.056, 15474004.
27. Köster M, Lykke-Andersen S, Elnakady YA, Gerth K, Washausen P, Höfle G, Sasse F, Kjems J, Hauser H. Ratjadones inhibit nuclear export by blocking CRM1/exportin 1. Exp Cell Res 2003, 286:321-331. 10.1016/S0014-4827(03)00100-9, 12749860.
28. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, Elledge SJ. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008, 319:921-926. 10.1126/science.1152725, 18187620.
29. Kimura T, Hashimoto I, Nishikawa M, Yamada H. Nucleocytoplasmic transport of luciferase gene mRNA requires CRM1/Exportin1 and RanGTPase. Med Mol Morphol 2009, 42:70-81. 10.1007/s00795-009-0441-3, 19536614.
30. Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, Wong J, Robinson JA, Karn J, Varani G, Arts EJ. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog 2011, 7:e1002038. 10.1371/journal.ppat.1002038, 3098202, 21625572.
31. Daelemans D, Pauwels R, De Clercq E, Pannecouque C. A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc 2011, 6:925-933. 10.1038/nprot.2011.330, 21637207.
32. Wodrich H, Schambach A, Krausslich HG. Multiple copies of the Mason-Pfizer monkey virus constitutive RNA transport element lead to enhanced HIV-1 Gag expression in a context-dependent manner. Nucleic Acids Res 2000, 28:901-910. 10.1093/nar/28.4.901, 102582, 10648781.
33. Lomenick B, Jung G, Wohlschlegel J, Huang J. Target identification using drug affinity responsive target stability (DARTS). Curr Protoc Chem Biol 2011, 3:163-180. 3251962, 22229126.
34. Pace CN, McGrath T. Substrate stabilization of lysozyme to thermal and guanidine hydrochloride denaturation. J Biol Chem 1980, 255:3862-3865.
35. Hauber J, Bouvier M, Malim MH, Cullen BR. Phosphorylation of the rev gene product of human immunodeficiency virus type 1. J Virol 1988, 62:4801-4804. 253603, 2846891.
36. Wegeners AD, Jones LR. Phosphorylation-induced mobility shift in phospholamban in sodium dodecyl sulfate-polyacrylamide gels. J Biol Chem 1984, 259:1834-1841.
37. Yang X, Gabuzda D. Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. J Virol 1999, 73:3460-3466. 104113, 10074203.
38. Gegerfelt ASV, Alicea C, Valentin A, Morrow M, Rompay KKV, Ayash-Rashkovsky M, Markham P, Else JG, Marthas ML, Pavlakis GN. Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res Hum Retroviruses 2006, 22:516-528. 10.1089/aid.2006.22.516, 16796527.
39. Ratmeyer L, Zapp ML, Green MR, Vinayak R, Kumar A, Boykin DW, Wilson WD. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. Biochemistry 1996, 35:13689-13696. 10.1021/bi960954v, 8885849.
40. Ammaranond P, Sanguansittianan S. Mechanism of HIV antiretroviral drugs progress toward drug resistance. Fundam Clin Pharmacol 2012, 26:146-161. 10.1111/j.1472-8206.2011.01009.x, 22118474.
41. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012, 2:a007161. 3312400, 22474613.
42. Naji S, Ambrus G, Cimermančič P, Reyes JR, Johnson JR, Filbrandt R, Huber MD, Vesely P, Krogan NJ, Yates JR. Host cell interactome of HIV-1 Rev includes RNA helicases involved in multiple facets of virus production. Mol Cell Proteomics 2012, 11:M111.015313. 10.1074/mcp.M111.015313, 3322577, 22174317.
43. Arhel N, Kirchhoff F. Host proteins involved in HIV infection: new therapeutic targets. Biochim Biophys Acta 1802, 2010:313-321.
44. Buckheit RW, Allen TG, Alme A, Salgado M, O'Connell KA, Huculak S, Falade-Nwulia O, Williams TM, Gallant JE, Siliciano RF. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat Commun 2012, 3:716. 3549550, 22395607.
45. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009, 6:111. 10.1186/1742-4690-6-111, 2797771, 19961595.
46. Friedrich BM, Dziuba N, Li G, Endsley MA, Murray JL, Ferguson MR. Host factors mediating HIV-1 replication. Virus Res 2011, 161:101-114. 10.1016/j.virusres.2011.08.001, 21871504.
47. Khattab M. Targeting host factors: A novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009, 15:3472. 10.3748/wjg.15.3472, 2715971, 19630100.
48. Pérez-Vilaró G, Jungfleisch J, Saludes V, Scheller N, Giménez-Barcons M, Díez J. Host factors in viral life cycles. Math Model Nat Phenom 2012, 7:123-132.
49. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005, 11:1170-1172. 10.1038/nm1319, 16205738.
50. Bogerd H, Echarri A, Ross T, Cullen B. Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. J Virol 1998, 72:8627-8635. 110274, 9765402.
51. Hanly SM, Rimsky LT, Malim MH, Kim JH, Hauber J, Duc Dodon M, Le SY, Maizel JV, Cullen BR, Greene WC. Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev 1989, 3:1534-1544. 10.1101/gad.3.10.1534, 2482226.
52. Shida H. Role of Nucleocytoplasmic RNA Transport during the Life Cycle of Retroviruses. Front Microbiol 2012, 3:179. 3390767, 22783232.
53. Rawlinson SM, Pryor MJ, Wright PJ, Jans D. CRM1-mediated nuclear export of dengue virus RNA polymerase NS5 modulates interleukin-8 induction and virus production. J Biol Chem 2009, 284:15589-15597. 10.1074/jbc.M808271200, 2708855, 19297323.
54. Cerutti A, Maillard P, Minisini R, Vidalain P-O, Roohvand F, Pecheur E-I, Pirisi M, Budkowska A. Identification of a functional, CRM-1-dependent nuclear export signal in hepatitis C virus core protein. PLoS One 2011, 6:e25854. 10.1371/journal.pone.0025854, 3200325, 22039426.
55. Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, MacMillan J, Chook YM. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci USA 2013, 110:1303-1308. 10.1073/pnas.1217203110, 3557022, 23297231.
56. Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 2009, 69:6899-6905. 10.1158/0008-5472.CAN-09-0484, 2744372, 19690141.
57. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013, 161:117-127. 10.1111/bjh.12231, 23373539.
58. Yedavalli VS, Jeang KT. Trimethylguanosine capping selectively promotes expression of Rev-dependent HIV-1 RNAs. Proc Natl Acad Sci USA 2010, 107:14787-14792. 10.1073/pnas.1009490107, 2930441, 20679221.
59. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 1993, 160:81-88. 10.1016/0022-1759(93)90011-U, 7680699.
60. Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, Nakashima H, Fujii N. Pharmacophore Identification of a Specific CXCR4 Inhibitor, T140, Leads to Development of Effective Anti-HIV Agents with Very High Selectivity Indexes. Bioorg Med Chem 2000, 10:2633-2637.
61. Pauwels R, Andries K, Debyser Z, Van Daele P, Schols D, Stoffels P, De Vreese K, Woestenborghs R, Vandamme AM, Janssen CG. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:1711-1715. 10.1073/pnas.90.5.1711, 45949, 7680476.
62. Guo J, Wang W, Yu D, Wu Y. Spinoculation triggers dynamic actin and cofilin activity that facilitates HIV-1 infection of transformed and resting CD4 T cells. J Virol 2011, 85:9824-9833. 10.1128/JVI.05170-11, 3196392, 21795326.